SMA Project: New treatment strategies for children with Type II and III SMA

SMA Europe shared an interesting SMA project that still needs support. If you’re interested, please follow the job/reference number 👇 Job reference: KU00000806 Closing date: 5/09/18

Lives of adults with SMA (PRISM-SMA)

Spinal muscular atrophy (SMA) is one of the most common genetic causes of infant mortality, but adults can be affected. The latest study shows single symptom, mobility, symptoms Participants of 359 adults with SMA. Limitations with mobility or walking (98.6%) and the inability to do activities (98.6%) were the 2… Att fortsätt läsa

Phase II clinical trials with Reldesemtiv (CK-2127107) in Patients with Spinal Muscular Atrophy (SMA II-III)

presented in an oral presentation by John W. Day, MD, Ph.D., Professor of Neurology and Paediatrics (Genetics), Stanford University. This hypothesis-generating study met its primary goal. It fulfills the effect and safety profile. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and… Att fortsätt läsa

Spinraza i Danmark: Medicinrådet ønsker markant laver pris som Sverige, Norge og Tyskland vi spekulerer på hvorfor!

Enig, det er også uforståeligt for os, at Medicinrådet forlanger markant lavere priser i Danmark end det man har forhandlet og accepteret i andre sammenlignelige lande som Norge og Sverige, Tyskland og Schweiz.” Det er pinligt, at Danmark ikke giver denne banebrydende medicin til sine SMA patienter Lisbeth Koed Doktor… Att fortsätt läsa